{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:57Z","timestamp":1787003697387,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Comparative analytical assessment (CAA) between the reference product and the proposed product forms the basis of the biosimilarity demonstration. Though Dynamic Light Scattering (DLS) has been implemented for CAA, its capability beyond signature peak for similarity assessments has remained unexplored. Herein, we have developed a innovative forced degradation based sweet spot method consisting of signature peak, temperature range, increment and hold time using high throughput-DLS (HT-DLS) to show similarity in hydrodynamic size between products. In our study, we used rituximab, its biosimilars, and insulin analogs as model products to demonstrate product similarity in hydrodynamic size (D\n                    <jats:sub>h<\/jats:sub>\n                    ) size through the HT-DLS sweet spot approach. Our data indicate that temperature range, temperature increment, hold time, and regularization algorithm, all play a role in showing analytical similarity in D\n                    <jats:sub>h<\/jats:sub>\n                    size. Our data also indicate that establishing DLS signature peaks of the products is insufficient to show analytical similarity in D\n                    <jats:sub>h<\/jats:sub>\n                    size distribution. Additionally, the temperature range (sweet spot) varies from product to product. Principal component analysis modeling was used for detailed data interpretation. Overall, our HT-DLS based sweet spot method provided informative data to support similarity in D\n                    <jats:sub>h<\/jats:sub>\n                    size distribution.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-97377-6","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T18:43:01Z","timestamp":1763836981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Innovative approach to support therapeutic proteins\u2019 similarity in hydrodynamic size using high-throughput dynamic light scattering and forced degradation"],"prefix":"10.1038","volume":"15","author":[{"given":"Ashwinkumar","family":"Bhirde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Harish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Trunfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella F.","family":"de Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"97377_CR1","doi-asserted-by":"crossref","unstructured":"Joshi, D. et al. Biosimilars in oncology: latest trends and regulatory status. Pharmaceutics 14 (12). (2022).","DOI":"10.3390\/pharmaceutics14122721"},{"issue":"4","key":"97377_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.6004\/jadpro.2021.12.4.7","volume":"12","author":"MB May","year":"2021","unstructured":"May, M. B., Taucher, K. D. & Vogel, W. H. Practical considerations for integrating biosimilars into clinical practice. J. Adv. Pract. Oncol. 12 (4), 431\u2013438. https:\/\/doi.org\/10.6004\/jadpro.2021.12.4.7 (2021).","journal-title":"J. Adv. Pract. Oncol."},{"issue":"11","key":"97377_CR3","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1002\/cnr2.1720","volume":"5","author":"RD Bachu","year":"2022","unstructured":"Bachu, R. D. et al. Oncology biosimilars: new developments and future directions. Cancer Rep. (Hoboken). 5 (11), e1720. https:\/\/doi.org\/10.1002\/cnr2.1720 (2022).","journal-title":"Cancer Rep. (Hoboken)"},{"key":"97377_CR4","doi-asserted-by":"publisher","first-page":"832059","DOI":"10.3389\/fbioe.2022.832059","volume":"10","author":"N Nupur","year":"2022","unstructured":"Nupur, N., Joshi, S., Gulliarme, D. & Rathore, A. S. Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Front. Bioeng. Biotechnol. 10, 832059. https:\/\/doi.org\/10.3389\/fbioe.2022.832059 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"97377_CR5","doi-asserted-by":"publisher","unstructured":"Joshi, S. & Rathore, A. S. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study. BioDrugs. 34(2), 209\u2013223. https:\/\/doi.org\/10.1007\/s40259-020-00404-3.  (2020).","DOI":"10.1007\/s40259-020-00404-3"},{"key":"97377_CR6","doi-asserted-by":"publisher","unstructured":"Dyck, Y. F. K. et al. Forced degradation testing as complementary tool for biosimilarity assessment. Bioeng. (Basel). 6 (3). https:\/\/doi.org\/10.3390\/bioengineering6030062 (2019).","DOI":"10.3390\/bioengineering6030062"},{"issue":"7","key":"97377_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/19420862.2017.1347741","volume":"9","author":"K Pisupati","year":"2017","unstructured":"Pisupati, K. et al. Biosimilarity under stress: A forced degradation study of Remicade(R) and Remsima. MAbs 9 (7), 1197\u20131209. https:\/\/doi.org\/10.1080\/19420862.2017.1347741 (2017).","journal-title":"MAbs"},{"issue":"29","key":"97377_CR8","doi-asserted-by":"publisher","first-page":"16199","DOI":"10.1021\/jp5034068","volume":"118","author":"AA Bhirde","year":"2014","unstructured":"Bhirde, A. A., Hassan, S. A., Harr, E. & Chen, X. Role of albumin in the formation and stabilization of nanoparticle aggregates in serum studied by continuous photon correlation spectroscopy and multiscale computer simulations. J. Phys. Chem. C Nanomater. Interfaces. 118 (29), 16199\u201316208. (2014).","journal-title":"J. Phys. Chem. C Nanomater Interfaces"},{"issue":"4","key":"97377_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12551-016-0218-6","volume":"8","author":"J Stetefeld","year":"2016","unstructured":"Stetefeld, J., McKenna, S. A. & Patel, T. R. Dynamic light scattering: a practical guide and applications in biomedical sciences. Biophys. Rev. 8 (4), 409\u2013427. https:\/\/doi.org\/10.1007\/s12551-016-0218-6 (2016).","journal-title":"Biophys. Rev."},{"issue":"6","key":"97377_CR10","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1039\/c6nr08579b","volume":"9","author":"AA Bhirde","year":"2017","unstructured":"Bhirde, A. A., Sindiri, S., Calco, G. N., Aronova, M. A. & Beaucage, S. L. Algorithm-driven high-throughput screening of colloidal nanoparticles under simulated physiological and therapeutic conditions. Nanoscale 9 (6), 2291\u20132300. https:\/\/doi.org\/10.1039\/c6nr08579b (2017).","journal-title":"Nanoscale"},{"issue":"4","key":"97377_CR11","doi-asserted-by":"publisher","first-page":"046001","DOI":"10.1088\/1478-3975\/aa776a","volume":"14","author":"E Dahal","year":"2017","unstructured":"Dahal, E. et al. Structural evaluation of an amyloid fibril model using small-angle x-ray scattering. Phys. Biol. 14 (4), 046001. https:\/\/doi.org\/10.1088\/1478-3975\/aa776a (2017).","journal-title":"Phys. Biol."},{"issue":"11","key":"97377_CR12","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1016\/j.xphs.2020.08.013","volume":"109","author":"A Bhirde","year":"2020","unstructured":"Bhirde, A. et al. High performance size exclusion chromatography and High-Throughput dynamic light scattering as orthogonal methods to screen for aggregation and stability of monoclonal antibody drug products. J. Pharm. Sci. 109 (11), 3330\u20133339. https:\/\/doi.org\/10.1016\/j.xphs.2020.08.013 (2020).","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"97377_CR13","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/s41598-020-59346-z","volume":"10","author":"T Xie","year":"2020","unstructured":"Xie, T. et al. The ELISA detectability and potency of pegfilgrastim decrease in physiological conditions: key roles for aggregation and individual variability. Sci. Rep. 10 (1), 2476. https:\/\/doi.org\/10.1038\/s41598-020-59346-z (2020).","journal-title":"Sci. Rep."},{"issue":"8","key":"97377_CR14","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.xphs.2018.04.017","volume":"107","author":"AA Bhirde","year":"2018","unstructured":"Bhirde, A. A., Chiang, M. J., Venna, R., Beaucage, S. & Brorson, K. High-Throughput In-Use and stress size stability screening of protein therapeutics using Algorithm-Driven dynamic light scattering. J. Pharm. Sci. 107 (8), 2055\u20132062. https:\/\/doi.org\/10.1016\/j.xphs.2018.04.017 (2018).","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"97377_CR15","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.xphs.2022.06.013","volume":"111","author":"M Kim","year":"2022","unstructured":"Kim, M. et al. Failure mode identification of insulin drug Products - Impact of relevant stress conditions on the quality of the drug. J. Pharm. Sci. 111 (9), 2451\u20132457. https:\/\/doi.org\/10.1016\/j.xphs.2022.06.013 (2022).","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"97377_CR16","doi-asserted-by":"publisher","first-page":"e4676","DOI":"10.1002\/bmc.4676","volume":"33","author":"LA Hassan","year":"2019","unstructured":"Hassan, L. A., Al-Ghobashy, M. A. & Abbas, S. S. Evaluation of the pattern and kinetics of degradation of adalimumab using a stability-indicating orthogonal testing protocol. Biomed. Chromatogr. 33 (12), e4676. https:\/\/doi.org\/10.1002\/bmc.4676 (2019).","journal-title":"Biomed. Chromatogr."},{"issue":"2","key":"97377_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40259-019-00342-9","volume":"33","author":"J Hermosilla","year":"2019","unstructured":"Hermosilla, J. et al. Comparative stability studies of different Infliximab and biosimilar CT-P13 clinical solutions by combined use of physicochemical analytical techniques and Enzyme-Linked immunosorbent assay (ELISA). BioDrugs 33 (2), 193\u2013205. https:\/\/doi.org\/10.1007\/s40259-019-00342-9 (2019).","journal-title":"BioDrugs"},{"key":"97377_CR18","doi-asserted-by":"publisher","first-page":"122359","DOI":"10.1016\/j.jchromb.2020.122359","volume":"1159","author":"YA Trabik","year":"2020","unstructured":"Trabik, Y. A., Moenes, E. M., Al-Ghobashy, M. A., Nebsen, M. & Ayad, M. F. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: effect of structural optimization and glycoengineering. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 1159, 122359. https:\/\/doi.org\/10.1016\/j.jchromb.2020.122359 (2020).","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"issue":"7","key":"97377_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.drudis.2017.01.005","volume":"22","author":"A Giuliani","year":"2017","unstructured":"Giuliani, A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov. Today. 22 (7), 1069\u20131076. https:\/\/doi.org\/10.1016\/j.drudis.2017.01.005 (2017).","journal-title":"Drug Discov Today"},{"key":"97377_CR20","doi-asserted-by":"publisher","first-page":"122872","DOI":"10.1016\/j.saa.2023.122872","volume":"299","author":"MK Shukla","year":"2023","unstructured":"Shukla, M. K. et al. Identification of monoclonal antibody drug substances using non-destructive Raman spectroscopy. Spectrochim. Acta Mol. Biomol. Spectrosc. 299, 122872. https:\/\/doi.org\/10.1016\/j.saa.2023.122872 (2023).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97377-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97377-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97377-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T01:02:54Z","timestamp":1764378174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97377-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97377"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97377-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41481"}}